SM
RVNC

Sciencast Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Sciencast Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$165K Buy
+11,209
New +$173K 0.04% 370

Other funds holding RVNC

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Sciencast Management's RVNC Position: Q2 2022 in Review

Sciencast Management opened a new position in Revance Therapeutics, Inc. (RVNC) in Q2 2022: 11,209 shares worth $165K. The stake represents 0.04% of the portfolio and ranks #370 among its holdings.

161 funds tracked by Wall St. Rank hold RVNC as of Q2 2022.

  • Sciencast Management held 11,209 shares of Revance Therapeutics, Inc. worth $165K as of Q2 2022.
  • Revance Therapeutics, Inc. was a new Sciencast Management position in Q2 2022.
  • Revance Therapeutics, Inc. made up 0.04% of Sciencast Management's portfolio in Q2 2022, its #370 holding.
  • 161 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2022.

Based on Sciencast Management's 13F filing for Q2 2022, filed 3 Aug 2022.